MediWound (NASDAQ:MDWD) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD)’s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $17.72 and traded as low as $17.61. MediWound shares last traded at $17.73, with a volume of 23,348 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of MediWound in a research note on Friday, January 10th.

MediWound Stock Down 4.8 %

The firm has a fifty day simple moving average of $18.20 and a 200-day simple moving average of $17.72. The company has a market capitalization of $191.25 million, a P/E ratio of -6.11 and a beta of 0.81.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the company earned ($0.24) earnings per share. On average, sell-side analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Investor AB bought a new position in shares of MediWound during the third quarter worth about $15,750,000. Yelin Lapidot Holdings Management Ltd. grew its holdings in shares of MediWound by 13.4% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after buying an additional 100,618 shares in the last quarter. Rosalind Advisors Inc. grew its holdings in shares of MediWound by 22.3% during the third quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares in the last quarter. Essex Investment Management Co. LLC grew its holdings in shares of MediWound by 30.7% during the fourth quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after buying an additional 35,012 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after buying an additional 70,367 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.